Full board meetings occur Monday afternoons at 4:30 PM Eastern. Complete study submissions received by the EOB Monday, will be reviewed at the Monday meeting of the following week. To ensure a timely review of your study, please refer to the Additional Information...
This is the fourth of our “Ask the Expert” blogs, a series featuring the wisdom and seasoned insight of Pearl Pathways Advisors and Consultant Advisors. Gretchen Parker, PhD, RAC, CIP, Pearl’s IRB Co-Chair, Senior Advisor, was interviewed for this piece. If you have...
In clinical research, the purpose of institutional review board (IRB) review is to ensure the rights and welfare of human subjects are protected. Unnecessary delays in the IRB review process can prevent treatments from getting to patients and slow the improvement of...
Pearl Pathways’ own Director of RA/QA Services Becki Nowatzke was honored to serve on the planning committee for this compelling event featuring an outstanding slate of keynote speakers including Jonathan Blum (Principal Deputy Administrator & COO, U.S....
The International Council for Harmonization (ICH) released an updated version of its guideline on general considerations for clinical trials, RAPS reports. ICH released the guideline, E8(R1), earlier this May for public consultation on the draft.The revised guideline...
